This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| GABA_A receptor | |
|---|---|
| Name | GABA_A receptor |
| Organism | Homo sapiens |
GABA_A receptor The GABA_A receptor is a pentameric ligand-gated ion channel that mediates fast inhibitory neurotransmission in the vertebrate central nervous system. It binds the neurotransmitter γ-aminobutyric acid and conducts chloride ions to modulate neuronal excitability, interacting functionally with diverse signaling proteins, synaptic scaffolds, and pharmacological agents linked to neurology and psychiatry. The receptor's significance spans basic neuroscience, clinical neurology, and drug development programs across academic institutions and pharmaceutical companies.
The receptor is assembled from multiple homologous subunit gene families including alpha, beta, gamma, delta, epsilon, theta, pi, and rho, each encoded by distinct loci on human chromosomes studied in laboratories at institutions such as Harvard University, Max Planck Society, University of Oxford, Columbia University, and Stanford University. High-resolution structures obtained by cryo-EM groups at Massachusetts Institute of Technology, EMBL-EBI, and University of Cambridge reveal transmembrane domains with M1–M4 helices and extracellular ligand-binding domains reminiscent of homologous proteins from the nicotinic receptor family researched at Salk Institute and Rockefeller University. Genetic mapping efforts at Broad Institute and clinical centers like Mayo Clinic associate specific subunit isoforms with regional expression patterns in the hippocampus, amygdala, cerebellum, and cerebral cortex, informing studies at Johns Hopkins University and University College London. Structural studies also reference conserved motifs characterized by the work of researchers linked to awards such as the Nobel Prize in Physiology or Medicine and collaborations with national resources like the National Institutes of Health.
A broad pharmacology encompasses benzodiazepines, barbiturates, neurosteroids, ethanol, general anesthetics, and several experimental ligands developed in partnerships between Pfizer, GlaxoSmithKline, Roche, and academic spinouts from University of California, San Francisco. Classic benzodiazepines such as diazepam were characterized in clinical trials at centers like Mayo Clinic and Cleveland Clinic and are studied alongside nonbenzodiazepine hypnotics developed at Eli Lilly and Company. Barbiturate actions were foundational in studies at McGill University and University of Toronto, while neurosteroid modulation has been pursued by teams at Yale University and University of Pennsylvania. Alcohol effects on the receptor have been explored in epidemiological cohorts coordinated by Johns Hopkins Bloomberg School of Public Health and Imperial College London. Positive and negative allosteric modulators are targets in translational programs funded by agencies such as the National Science Foundation and coordinated with regulatory bodies including the Food and Drug Administration.
GABA_A receptor-mediated currents shape inhibitory postsynaptic potentials in circuits studied in model systems at Salk Institute, Cold Spring Harbor Laboratory, and Carnegie Institution for Science. Fast synaptic inhibition in the hippocampus and cortex involves receptors anchored by gephyrin and interacting with cell-adhesion molecules analyzed by groups at Karolinska Institutet and Weizmann Institute of Science. In vivo recordings from laboratories affiliated with Columbia University and University of California, Berkeley demonstrate roles in oscillatory activity such as theta and gamma rhythms relevant to work at MIT and Princeton University. Dysfunctional inhibition has been linked to seizure networks examined in clinical centers like Massachusetts General Hospital and UCSF Medical Center, and to neuropsychiatric phenomena investigated at McLean Hospital and Mount Sinai Hospital.
During developmental windows characterized by studies at Children's Hospital Boston and Great Ormond Street Hospital, the receptor can produce depolarizing influences due to immature chloride gradients shaped by transporters described in publications from University of Geneva and Seoul National University. Developmental regulation of subunit expression is a subject of research at University of California, San Diego and University of Melbourne, linking early GABAergic signaling to synaptogenesis, dendritic growth, and critical-period plasticity studied alongside classic work from Johns Hopkins University School of Medicine and University of Chicago. Plasticity phenomena including inhibitory long-term potentiation and homeostatic synaptic scaling are investigated in collaborations involving Howard Hughes Medical Institute and research programs funded by the Wellcome Trust.
Mutations and polymorphisms in subunit genes have been implicated in epilepsy syndromes, intellectual disability, insomnia, anxiety disorders, and schizophrenia, with genotype–phenotype correlations reported by consortia including International League Against Epilepsy and genome studies coordinated by the 1000 Genomes Project and UK Biobank. Clinical genetics units at Great Ormond Street Hospital, Boston Children's Hospital, and Stanford Children's Health have reported rare de novo variants in alpha and beta subunits linked to severe epileptic encephalopathies. Large-scale association studies from Broad Institute and psychiatric genetics consortia implicate regulatory loci that intersect with pharmacogenomic findings from National Institute of Mental Health and multinational trials overseen by World Health Organization collaborations.
Experimental approaches include electrophysiology (patch clamp) developed in laboratories at Max Planck Institute for Biophysical Chemistry and University of California, San Diego, structural biology (cryo-EM) from centers like Harvard Medical School and European Molecular Biology Laboratory, and in vivo imaging applied at University of California, Los Angeles and University of Pennsylvania. High-throughput screening platforms used by biotechnology firms such as Genentech and academic core facilities enable discovery of subtype-selective modulators, while clinical trial infrastructure at hospitals including Massachusetts General Hospital and regulatory oversight by the Food and Drug Administration guide translation to therapeutics targeting insomnia, anxiety, epilepsy, and anesthesia. Ongoing interdisciplinary consortia link molecular research with systems neuroscience at institutions such as Allen Institute for Brain Science and policy bodies including the European Medicines Agency.
Category:Neurotransmitter receptors